Randomized trials conducted by the Intergroupe Française du Myelome (IFM) demonstrate that the use of high-dose chemotherapy (HDCT) and stem cell transplantation (SCT) improves event-free (EFS) and overall survival (OS) in younger patients with multiple myeloma (MM). Nevertheless, current HDCT regimens remain inadequate as all patients ultimately relapse following SCT. In an attempt to improve the OS of MM patients post-SCT we used an escalated HDCT regimen incorporating both intensified melphalan (160 mg/m 2 ) and fractionated total body irradiation (12 Gy) to maximize the dose response of myeloma cells to these agents and included infusional etoposide 60 mg/kg in an attempt to eradicate clonal B cells potentially contributing to the myeloma clone. One hundred patients with MM received this intensified SCT regimen. The 100-day treatment-related mortality was 12% predominantly reflecting the development of interstitial pneumonitis (IP) in 28% of patients of whom 7/28 (25%) died. The predicted 5-year OS and EFS following the diagnosis of MM were 60% and 35%, respectively. The median OS from the time of transplant is 41 months and the median EFS is 28 months. More than two prior chemotherapy regimens, previous radiation therapy (RT) and the presence of an abnormal karyotype involving chromosomes 11 or 13 were significantly predictive of poor outcome. responses can be obtained even in patients previously refractory to this drug, however severe but reversible myelosuppression is observed, with toxic death rates of 10-20%. [4] [5] [6] [7] [8] With the advent of autologous bone marrow (ABMT) and peripheral blood stem cell transplantation (SCT), melphalan-based myeloablative regimens have been tested in selected younger patients. Toxic death rates related to high-dose melphalan have subsequently fallen to between 2 and 11%.
conventional-dose melphalan-based chemotherapy, objective responses are observed in 50-60% of patients, although these are rarely durable and the median overall survival (OS) is less than 3 years. 1 Using higher dose melphalan 2, 3 responses can be obtained even in patients previously refractory to this drug, however severe but reversible myelosuppression is observed, with toxic death rates of 10-20%. [4] [5] [6] [7] [8] With the advent of autologous bone marrow (ABMT) and peripheral blood stem cell transplantation (SCT), melphalan-based myeloablative regimens have been tested in selected younger patients. Toxic death rates related to high-dose melphalan have subsequently fallen to between 2 and 11%. [9] [10] [11] Reported response rates in single center phase II trials of SCT incorporating high-dose melphalan range between 25-80% (reflecting the variable response criteria employed), however the median duration of response from the time of transplant generally fails to exceed 2-3 years. [12] [13] [14] [15] In the only published randomized controlled trial (RCT) of intensive therapy, the Intergroupe Français du Myelome (IFM) demonstrated the superiority of high-dose melphalan and total body irradiation (TBI) with ABMT support over conventional-dose chemotherapy. The projected 5-year overall survival (OS) following melphalan 140 mg/m 2 and TBI 8 Gy supported by ABMT was 52% compared with only 12% in the standard chemotherapy arm. The probabilities of OS and event-free survival (EFS) 5 year after diagnosis for those patients who actually received a transplant were 68% and 39%, respectively. Although the results of this trial clearly constitute 16 a major advance in myeloma therapy all patients relapse post-transplant.
As the vast majority of the patients treated with either ABMT or allogeneic BMT eventually relapse, drug resistance apparently remains a significant obstacle to cure and more effective high-dose regimens and/or maintenance therapies are required to further improve outcome. In this regard in vitro evidence of a dose-response of myeloma cells to the effects of radiation 17 together with clinical evidence of the efficacy of escalating melphalan guided our decision to utilize escalated doses of these agents in an attempt to increase the proportion of malignant cells killed during the transplant induction therapy. Furthermore, it was reasoned at the time of study initiation that etoposide 18, 19 may help eliminate the putative germinal center B cells potentially contributing to the malignant plasma cell clone on an ongoing basis. In essence this transplant induction regimen constitutes an escalation of the IFM induction regimen used in the randomized transplant trial described above. This report describes the results of transplanting 100 myeloma patients with this intensified transplant regimen and describes the enhanced toxicity observed and survival data obtained.
Patients and methods
A total of 100 patients with MM were treated on this regimen between March 1992 and June 1998. The inclusion criteria were: age Ͻ65 years, stage II-III disease according to the Durie-Salmon classification, 20 ECOG performance status р2, chemotherapy sensitive disease (Ͼ50% reduction of paraprotein or Bence-Jones proteinuria (BJP)), and normal left ventricular and pulmonary function as assessed by MUGA scan and pulmonary function tests, respectively. Bone marrow cytogenetic analysis at diagnosis (or at referral if not previously performed), serum lactate dehydrogenase (LDH), beta-2-microglobulin (␤ 2 M) and C-reactive protein (CRP) levels were assessed prior to HDCT.
PBPC mobilization
To mobilize peripheral blood stem cells, patients received (1995-1998) followed by G-CSF 10 g/kg/day. Stem cells were harvested on a Fenwall CS 3000 (Baxter, Deerfield, IL, USA) or COBE Spectra (Cobe, Lakewood, CO, USA), then cryopreserved using rate-controlled freezing. Two patients who failed peripheral blood stem cell collections received autologous bone marrow.
Intensive therapy and autotransplant
The high-dose regimen consisted of etoposide 60 mg/kg by 5-h infusion on day Ϫ4, melphalan 160 mg/m 2 on day Ϫ3 and fractionated TBI 12 Gy (2 Gy twice a day ϫ 6 doses given on days Ϫ2, Ϫ1, 0). Lung shielding produced an effective lung dose of 12 Gy. On day 0 the cryopreserved autograft was infused. Patients were nursed in single rooms in reverse isolation from day 0 until the absolute neutrophil count (ANC) was у0.5 ϫ 10 9 /l for 2 consecutive days. Antimicrobial prophylaxis consisted of sulphamethoxazole or ciprofloxacin starting on day ϩ1. Patients received GM-CSF (5 g/kg/day) from day 1 until the ANC was у1.0 ϫ 10 9 /l for 3 consecutive days. Patients seronegative for cytomegalovirus received CMV-negative blood products. Packed red blood cells and platelets were transfused as required to maintain hemoglobin Ͼ8 g/l and platelets Ͼ10 ϫ 10 9 /l. All cellular blood products were irradiated with 1500 cGy prior to transfusion. Empiric antibiotic therapy was initiated for fevers Ͼ38.5°C and maintained until the ANC was у0.5 ϫ 10 9 /l.
Maintenance therapy
Recombinant alpha interferon (IF) was started no sooner than 3 months after SCT, provided the patient had adequate engraftment, obtained financial coverage for the drug and was agreeable to its use. The target IF dose was 3 million units s.c. three times per week, continued until the time of disease progression.
Evaluation
Patients were followed with serum and urine protein electrophoresis performed at the initial 3-month post-transplant evaluation and then every 6 months. Bone marrow biopsies were not routinely performed unless new symptoms were reported, or a rising immunoglobulin level suggestive of progressive disease was noted. Complete remission (CR) was defined as the total absence of serum M-protein and Bence-Jones proteinuria by immunofixation and less than 5% plasma cells in marrow. A partial remission (PR) was defined as a Ͼ50% reduction in the Mcomponent in serum or a 75% reduction in urinary paraprotein. 'Stable' disease (SD) was defined as less than a 50% decrease in serum or urinary paraprotein. Progressive disease (PD) was defined as the reappearance of serum or urine paraprotein in complete responders, the development of new lytic lesions (new isolated vertebral compression fractures were inadequate to establish disease progression) or a Ͼ25% increase in serum paraprotein or urine paraprotein. The six patients with non-secretory myeloma had Ͻ5% plasma cells seen on bone marrow examination post transplant but had residual radiological abnormalities and were therefore coded as partial responders. Interstitial pneumonitis (IP) was defined as tachypnea or cough with hypoxemia and diffuse pulmonary infiltrates present on chest Xray. Organ toxicity was graded according to the National Cancer Institute of Canada (NCIC) criteria.
Interim analysis of this regimen raised concerns about the observed high incidence of pneumonitis. At that time all newly diagnosed patients were being enrolled on multicenter randomized phase III trials and only pre-treated patients receiving more than 6 months prior therapy received the phase II regimen described here. It was anticipated that the closure of phase III trials would allow treatment of a more robust patient population with a resulting decrease in treatment-related mortality. When a decline in the treatment-related mortality was not subsequently observed the study was halted and the regimen discontinued.
Statistical analysis
Descriptive statistics were performed using SPSS software (SPSS, Chicago, IL, USA). Engraftment data were calculated from day of stem cell re-infusion. Event-free and overall survival curves were generated using the KaplanMeier method 21 and calculated both from the date of diagnosis and date of SCT. Events were defined as myeloma relapse, treatment-related toxic deaths and deaths from all other causes. The log-rank test was used to compare the survival of different subgroups. 22 The following variables were examined:
, CRP (Ͻ/Ͼ0.4 mg/dl), LDH (Ͻ/Ͼ190 U/l), creatinine at transplant (normal/abnormal) abnormal karyotype, immunoglobulin isotype (IgA vs other), stage (I-II vs III), sex, interval between diagnosis and autotransplant (Ͻ/Ͼ1 year), number of prior CT regimens (Յ2/Ͼ2), previous radiation therapy, age at SCT (Ͻ/Ͼ45 years or Ͻ/Ͼ60 years) and remission status post-SCT (CR vs other). A Cox regression analysis was performed with stepwise inclusion of all variables with a univariate analysis P value of р0.20.
Results

Patients
The patient and disease characteristics are listed in Table 1 . There were 60 males and 40 females and the median age at diagnosis was 52 years (range, 32-65). The median interval from diagnosis until SCT was 16 months (7-90). The median number of previous chemotherapy regimens was two (range, 1-4). Forty patients had received prior radiation to areas of symptomatic skeletal disease, including 14 who had radiation to the chest area. At the time of transplant 94 patients had chemosensitive disease and six had stable myeloma.
PBPC collection and engraftment
The median CD34 ϩ cell yield was 6.4 ϫ 10 6 /kg. The median number of days to achieve an ANC of Ͼ0.5 was 10 (range, 0-30), the median time to an unsupported platelet count of Ͼ20 was 12 days (range, 6-350) and the median number of days of hospitalization was 23 (range, 13-81). Five patients remained platelet-dependent at 2 months post transplant. One patient died on day 100 due to an intracerebral hemorrhage whilst still platelet transfusiondependent. Four patients eventually demonstrated platelet engraftment between days 65 and 200. Two of these patients had received reinfused 'back-up marrow' with no discernable improvement in hematopoietic recovery. Table 1 Characteristics of patients and disease 
Acute toxicity
The 100-day TRM was 12% with an overall TRM of 15%. Deaths were due to interstitial pneumonitis (n = 7), typhilitis (n = 2), hepatic failure secondary to re-activated hepatitis B (n = 1), sepsis (n = 3), cerebral hemorrhage (n = 1) and thrombotic cerebral infarct (n = 1). Twelve treatmentrelated deaths occurred within 100 days of transplant, two deaths between days 100 and 120, and one death approximately 5 months post transplant. Twenty eight of 100 (28%) patients developed interstitial pneumonitis (IP) including the 7/28 (25%) fatal episodes. The median time to onset of IP was 63 days (range, 5-230), with 25 cases diagnosed within the initial 100 days of transplant and another three patients developing initial symptoms during this period. A potential infective agent was isolated from sputum or bronchial washings in six patients. Although the timing, radiological features and clinical course were felt to be more consistent with radiation pneumonitis in these patients, appropriate antimicrobial therapy was instituted in each case. The other major non-hematological toxicities included sepsis and mucositis (Table 2) . Thirty-seven percent of patients had confirmed bacteremia or radiological evidence of lobar pneumonia. Grade III/IV mucositis (unable to eat/Ϯ parenteral feeding) was observed in most patients, the majority of whom required narcotic infusion for pain relief. Three patients developed a severe peripheral neuropathy in the immediate post-transplant period, thought to be secondary to etoposide and/or previous vincristine. 23 
Late toxicity
High-dose treatment likely contributed to late toxicities in six patients. Two patients have developed secondary myelodysplasia (chronic myelomonocytic leukemia (CMML), refractory anemia with ringed sideroblasts (RARS)). Previous therapy involved 18 cycles of melphalan and prednisone in the patient developing CMML and three different regimens of chemotherapy (including nine cycles of melphalan and prednisone) in the patient with RARS; neither patient had received prior RT. No cases of secondary AML have been seen, however three patients have developed solid tumors 18-24 months following transplant. A female non-smoker was diagnosed with metastatic non-small cell lung cancer and is currently receiving palliative chemotherapy. A 52-year-old male was found to have metastatic prostate cancer 18 months after SCT, and has since died. Another male developed papillary thyroid carcinoma coincidentally at the time of relapse and has died of MM. A severe cardiomyopathy developed 2 years post transplant in a 56-year-old female who subsequently died of relapsed MM. This patient was a non-smoker with no known risk factors for ischemic heart disease other than her age. There were no echocardiographic features or clinical signs to suggest a diagnosis of cardiac amyloidosis, however an endomyocardial biopsy was not performed.
Response rates and survival
Fourteen patients died prior to the initial 3 month posttransplant staging visit. In the remaining 86 patients, 9/86 (10%) achieved a complete remission, 61/86 (71%) demonstrated a partial response and 16/86 (19%) had stable disease. The overall response rate was therefore 81%. Interferon was commenced in 37/86 (43%) patients surviving beyond 3 months. The predominant reasons for not starting interferon were ongoing fatigue, poor engraftment post transplant or lack of financial coverage for this agent.
At the time of analysis, 69 of 100 patients are alive with a median follow-up from diagnosis of MM in survivors of 34 months (range, 13-124 months). The median overall survival (OS) for all patients from the time of diagnosis is 72 months, with a standard error (s.e.) of 13 months (Figure 1 ). The median EFS is 47 months (s.e. 6 months) (Figure 2 ). The Kaplan-Meier estimates of the OS and EFS 5-years following the diagnosis of MM are 60% and 35%.
The median duration of post-transplant follow-up in surviving patients is 13 months (range, 3-73 months, mean, 20 months). The predicted median OS from the time of transplant is 41 months (s.e. 9 months) ( Figure 3 ) and the median EFS is 28 months (s.e. 5 months) (Figure 4) . The Kaplan-Meier estimates of the 5-year OS and EFS from the time of transplant are 35% and 15%, respectively.
The use of interferon post transplant was not associated with improved event-free or overall survival outcome P = 0.42 and 0.14, respectively. 
Prognostic factors
Age, stage, immunoglobulin isotype, karyotype, previous therapy, interval from diagnosis to transplant, remission status post transplant and markers of disease activity were analyzed for prognostic value (Table 3) . Pre-transplant assessment was available for LDH, ␤ 2 M and CRP in 94, 80 and 69 patients, respectively. Bone marrow cytogenetic results were available for 66 patients, with another seven patients having insufficient metaphases for adequate analysis. Thirteen patients (19%) were discovered to have a cytogenetic abnormality, the majority of which were complex and involved multiple chromosomes including chromosomes 11 or 13 (n = 11). When coded as dichotomous variables in univariate analysis, two factors were associated with both decreased OS and EFS: (1) having received more than two prior CT regimens (P = 0.002 and P = 0.02, respectively); and (2) an abnormal karyotype involving chromosomes 11 or 13 (P = 0.03 and P = 0.02, respectively). Prior RT was significantly predictive of decreased OS, but not EFS (P = 0.04) ( Table 3 ). In a multivariate model, more than two prior CT regimens retained prognostic significance for EFS (relative risk of event, 5; 95% CI: 2-14, P = 0.006), and abnormalities of chromosomes 11/13 were borderline significantly predictive of EFS (P = 0.08) and significantly associated with OS (relative risk of death, 10; 95%, CI: 3-33, P = 0.001).
Discussion
To further improve survival in MM patients undergoing autotransplant, high-dose chemotherapy regimens with greater tumoricidal efficiency or novel post-transplant maintenance therapies will be required. One approach to improving high-dose therapy regimens is to further increase the intensity of the transplant regimen. Indeed since the early studies of McElwain et al 2 with single agent melphalan, a number of groups have attempted to enhance transplant efficacy in small phase II studies through the addition of alternative active cytotoxic drugs and the inclusion of TBI in transplant induction regimens.
15,24-26
Table 3
Univariate analysis of prognostic factors Further pursuit of higher complete remission rates has led to the adoption of two sequential or 'tandem' melphalanbased transplants, a regimen pioneered by investigators in Little Rock, Arkansas. 27 This tandem transplant approach is currently being addressed in an ongoing randomized multicenter trial.
Prognostic factor Log-rank test (OS) Log-rank test (EFS) (P) (P)
Pursuing a similar logic (that higher complete remission rates will result in overall improved outcome) but in an attempt to reduce the resource constraints and quality of life issues raised by a two transplant procedure, we tested the feasibility of increasing the intensity of a single transplant. To explore the potential for this approach we used escalated doses of melphalan and TBI, and added infusional etoposide.
The Kaplan-Meier estimates of OS and EFS for 100 patients treated on this escalated transplant regimen 5 years following the diagnosis of MM are 60% and 35%. By comparison the probabilities of OS and EFS 5 years after diagnosis in the IFM randomized trial transplant arm were 68% and 39%, respectively. 16 It is important to note however that patients were not treated from diagnosis at our center and thus a selection bias is likely. As a more appropriate control EBMT 28 and Spanish registry 29 reports on 448 comparable patients reveal a reported median OS and EFS post transplant of 34 and 23 months with a TRM of 4-13%. In contrast, we report a predicted median OS and EFS from the time of transplant of 41 and 28 months, respectively. Overall we conclude that no significant survival benefit in favor of our escalated transplant regimen was apparent furthermore therapy-induced toxicity was substantial. The 100 day and overall TRM (12% and 15%, respectively) are considered unacceptably high, particularly in the absence of convincing improvement in outcome. In other phase II trials involving patients with both chemosensitive and chemoresistant MM, melphalan 140 mg/m 2 and TBI (8-12 Gy) have been utilized together, and in conjunction with other cytotoxics 11 or purged marrow 10 with reported TRM of 4-11%. 9, 16 The high overall TRM (15%) and incidence of interstital pneumonitis in our series (28%) is felt to reflect predominantly the use of escalated dose radiotherapy. Since TBI contributes to the increased TRM it is important to weigh the relative merits and disadvantages of including TBI in MM transplants. In this regard, Jagganath et al 30 improved response rates (from 56% to 100% in primary unresponsive MM, and from 33% to 58% in resistant relapsed MM) by adding TBI to melphalan. Nevertheless, an updated multivariate analysis of European registry data involving 384 patients suggests that the addition of TBI resulted in an inferior OS. 31 Thus, the survival benefit conferred by including TBI in MM induction regimen remains contentious and there are no published randomized trials comparing TBI containing and non-containing regimens in this disease. Since an increase in lung toxicity was the primary morbidity associated with use of TBI in our series it is important to note that the randomized IFM trial included 8 Gy of TBI in the transplant regimen and there were no recorded episodes of IP. 16 Nevertheless, others have reported significant lung toxicity in up to 16% of MM patients receiving TBI-containing transplant regimens 32 and in an EBMT registry study seven of 78 (9%) patients developed IP after the use of TBI. 31 Vesole et al 32 described a TRM of 25% in patients receiving melphalan 140 mg/m 2 plus TBI 850 cGy with autologous bone marrow rescue. Early toxic deaths were 'virtually eliminated' and the EFS was 'significantly improved' in a similar group of patients treated with 200 mg/m 2 melphalan and transplanted with both peripheral blood stem cells and autologous bone marrow. In our own institution, 45 patients have been transplanted with 200 mg/m 2 melphalan since closure of the phase II regimen described in this report; there have been no deaths due to transplant. Clearly the value of using TBI in MM transplants requires randomized trial analysis.
While we have focussed on TBI in enhancing the toxicity of our regimen it is also possible that the higher dose of melphalan may have contributed in a synergistic fashion to the increased incidence of IP as melphalan may cause pneumonitis even when used in isolation. 33 Finally, the unexpectedly high incidence of IP and TRM may also in part reflect more extensive pre-treatment (including radiotherapy) in our patient cohort. For example, the median time to transplant from diagnosis in this study was 16 months (with a median of two different regimens), compared to 5.5 months treatment with a uniform induction chemotherapy regimen as specified by the IFM protocol.
Use of etoposide in our escalated transplant regimen raises concerns about the late development of myelodysplastic syndromes (MDS) and secondary malignancies which are being increasingly recognized as long-term complications of ABMT. The relative contributions of prior therapy, the transplant regimen and the inclusion of TBI are unknown. 34 MDS was reported in 12% of MM patients 4 years after intensive therapy when more than three cycles of alkylating agent had been delivered pre-transplant, compared to 0% in patients who had never been treated with alkylating drugs. 35 Although most studies of secondary solid cancers have been in allograft recipients, limited data suggest that the cumulative incidence post autotransplant may be as high as 8.9% at 5 years. 36 With a modest median follow-up in our patients, the incidence of MDS and secondary solid cancers is 2% and 3%, respectively.
Standard practice post transplant is currently ␣-interferon or no further treatment. The IFN trial quoted above used interferon in all patients post transplant. No appropriately conducted study addressing use of interferon post transplant has yet been reported. Small trials not sufficiently powered to satisfactorily address the use of interferon post transplant have not surprisingly reached conflicting opinions about use of this drug. In one trial conducted at the Royal Marsden Hospital, 37 interferon was demonstrated to improve disease-free, but not overall survival post transplant. Although only 40 patients were randomized to each arm both OS and DFS were superior at 4.25 years in the interferon arm but, as relapses developed, the difference between the groups disappeared by 5.8 years. In contrast, as reported here, use of interferon vs no further therapy in similar numbers of patients post transplant could not be shown to confer a progression-free survival advantage. Randomized maintenance trials of interferon vs no further treatment and of interferon plus steroids vs interferon alone are ongoing in other large multi-center randomized trials and will hopefully further clarify this issue.
A number of prognostic factors previously shown by other groups to influence long-term survival following autotransplant were confirmed. 15, 16, 30, 38 In particular, the amount of prior therapy was significantly associated with the duration of OS and EFS. As with other investigators we demonstrate that aberrations of chromosomes 11 and 13 were associated with a worse EFS and OS. 38 However, unlike other studies we did not find that remission status post transplant predicted outcome. Using a rigorous definition of 'complete remission' necessitating complete absence of urine or serum paraprotein by immunofixation, the CR rate of 10% is lower than reported in other studies and may have contributed to the lack of prognostic significance.
In summary, the use of an escalated-dose transplant regimen in 100 chemosensitive myeloma patients results in high morbidity and TRM, without obviously improving survival. Prospective randomized trials specifically addressing the role of radiotherapy in MM transplant induction regimens are required. In the interim, we believe that the addition of etoposide and escalated dose TBI to a high-dose melphalan intensive therapy regimen for the treatment of MM cannot be recommended. Since the maximally tolerated doses of melphalan and radiation as a single high-dose therapy appear to have been reached, further study of sequential transplants and novel chemotherapy agents for transplant induction regimens or for long-term maintenance therapy should now be pursued.
